Techno Medica (6678) Q2 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2027 earnings summary
6 Nov, 2026Executive summary
H1 FY2027 net sales rose 8.5% YoY to ¥4,453.6m; operating profit increased 75.7% to ¥468.2m and profit rose 58.2% to ¥321.3m.
Net assets were ¥13,224.0m at September 30, 2026, with an equity-to-asset ratio of 85.4%.
Financial highlights
Gross profit increased to ¥2,155.6m from ¥1,956.9m; SG&A edged down to ¥1,687.4m from ¥1,690.4m.
Ordinary profit rose 65.0% YoY to ¥485.7m; net profit was ¥321.3m versus ¥203.1m.
Basic EPS increased to ¥48.94 from ¥29.31.
Outlook and guidance
FY2027 annual dividend forecast revised to ¥97 per share, comprising ¥0 for the first half and ¥97 at fiscal year-end; FY2026 annual dividend was ¥129.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Techno Medica
- Strong profit growth and higher EPS, but lower assets and reduced dividend forecast.6678
Q1 2027 - Q1 profits and revenue surged on robust sales, with full-year guidance maintained.6678Q1 2025
- Revenue up, profits down; overseas sales strong, cost pressures persist, outlook unchanged.6678Q2 2025
- Revenue steady, but profits fell sharply on higher costs; outlook unchanged.6678Q3 2025
- Revenue fell 3.7% as domestic delays offset strong overseas growth; profits declined year-over-year.6678Q4 2025
- Q1 FY2026 revenue fell 12.1% and net income dropped 90.5% year-over-year.6678Q1 2026
- Slight revenue and profit declines, but guidance and dividend unchanged; strong equity ratio.6678Q2 2026
- Revenue and profit surged on robust blood collection system sales; outlook remains strong.6678Q3 2026
- Revenue and profit rose on robust blood collection system sales, but FY2027 outlook is cautious.6678Q4 2026